<DOC>
	<DOCNO>NCT00465907</DOCNO>
	<brief_summary>Evaluate efficacy toxicity weekly combination chemotherapy Paclitaxel , Carboplatin Irinotecan Stage IIIb IV NSCLC maligant pleural effusion</brief_summary>
	<brief_title>Study Weekly Paclitaxel , Carboplatin Irinotecan Treat Lung Cancer</brief_title>
	<detailed_description>Lung cancer lead cancer death many country world include Singapore . Non-small cell lung cancer ( NSCLC ) consist 80-85 % lung cancer , major health problem . The main etiology lung cancer well recognize establish cigarette smoke account 80 % case western country . Due success anti-smoking campaig , anticipate see less smoke related lung cancer non-smoking related lung cancer rise rapidly . For eg , currently Singapore , smoke account 50-60 % lung cancer , particularly true female patient , smoke occur 30-40 % female lung cancer patient . It unclear significant difference fundamental biology smoke non-smoking related lung cancer , particularly area natural course disease , genetic change tumor cell , clinical presentation , response treatment survival . These potential aspect investigation .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histological cytological diagnosis nonsmall cell lung cancer . Malignant pleural effusion proven cytological examination . Patient must stage IIIB IV disease malignant pleural effusion . We plan recruit 16 patient smoked cigarette least 20 pack per year , 16 patient smoke exposed second hand smoke live person smoke 20 pack per year cigarette household 16 patient nonsmoker ( never smoke ) second hand smoking exposure household . The accrual stop number patient reach group . ECOG PS 0 , 1 2 . Measurable disease ( addition malignant pleural effusion ) . No prior chemotherapy metastatic recurrent disease . Patient may surgery radiation combine chemoradiation , neoadjuvant chemotherapy primary diagnosis . This kind chemotherapy count patient prior chemotherapy metastatic recurrent NSCLC . WBC &gt; 3500/uL ANC &gt; 2,000/uL , platelet &gt; 100,000/uL AST/ALT &lt; 3 X UNL , bilirubin &lt; 1.5 mg/dL ( &lt; 35 uM ) , creatinine &lt; 1.5 mg/dL ( &lt; 125uM men 90uM woman ) . Age &gt; 18 No history congestive heart failure , myocardial infarction lifethreatening arrthymia ( ventricular tachycardia , supraventricular tachycardia , brachycardia &lt; 40/min atrial fibrillation flutter ventricular rate &gt; 150/min ) within 6 month entry . Signed informed consent Negative mammogram ovary examination CT scan history breast cancer ovarian cancer female patient . Negative pregnancy test female menstruate patient within one week start chemotherapy use effective contraceptive method study . Patients brain metastasis eligible provide neurological abnormality stable improve whole brain radiation , stereostatic radiosurgery gamma knife treatment and/or dexamethasone 3 week patient fulfil eligibility criterion . ECOG performance status 3 worse . Any prior chemotherapy regimen metastatic recurrent disease . No measurable disease , even drainage pleural effusion . ANC &lt; 1,999/uL Bilirubin &gt; 1.5 mg/dL ( &gt; 35uM ) Plt &lt; 100,000/uL ALT/AST &gt; 3 x UNL Creatinine &gt; 1.5mg/dL ( &gt; 125uM ) Patient history congestive heart failure , myocardial infarction lifethreatening arrthymia ( ventricular tachycardia , supraventricular tachycardia , atrial fibrillation/flutter ventricular rate &gt; 150/min bradycardia &lt; 40/min ) within 6 month entry . Prior history breast cancer ovarian cancer female patient cancer except cured cervical carcinoma insitu skin cancer . Fasting blood sugar &gt; 200 mg/dL ( &gt; 14uM ) except patient dexamethasone brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>lung cancer malignant pleural effusion</keyword>
</DOC>